Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL833461 | 0.93 | ALDH1A1 (0.50) | TDP1BRD4ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL833462 | 0.93 | ALDH1A1 (0.50) | TDP1BRD4ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL833460 | 0.93 | ALDH1A1 (0.50) | TDP1BRD4ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL12015284 | 0.93 | TDP1 (0.53) | TDP1BRD4ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL12015283 | 0.92 | TDP1 (0.48) | TDP1BRD4ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL12015301 | 0.91 | TDP1 (0.50) | TDP1BRD4ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL835006 | 0.89 | TDP1 (0.48) | TDP1BRD4ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL835004 | 0.89 | TDP1 (0.48) | TDP1BRD4ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL12015308 | 0.89 | TDP1 (0.48) | TDP1BRD4ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL835005 | 0.89 | TDP1 (0.48) | TDP1BRD4ALDH1A1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497397-B2 | Substituted acrylamide derivative and pharmaceutical composition comprising the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-30 | — | — | US | disclosed |
| US-20120220593-A1 | Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220593-A1 | Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same | ACR, NAT1, C1S | TDP1 1470/4885BRD4 2459/4885ALDH1A1 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.